Neuren Pharmaceuticals (ASX:NEU) logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.
For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.
The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.
The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.